2834 – Page 95 – China Stock Advice

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: May15, 2013 Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: May15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) ex32-2.htm 5 EX-32.2]

By info| 2016-02-07T15:18:38+00:00 May 15th, 2013|Categories: BSPM, Chinese Stocks, SEC Original|Tags: 0001418133, 10-Q, 2013-05-15, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2013

[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: May15, 2013 Ronghua Wang Chief Executive Officer ex32-1.htm 4 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: May15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) ex32-2.htm 5 EX-32.2]

By info| 2016-02-07T15:19:31+00:00 May 15th, 2013|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: 0001418133, 10-Q, 2013-05-15, 2834, BSPM, PHARMACEUTICAL PREPARATIONS|0 Comments

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[SINOVAC APPOINTS ERNST & YOUNG HUA MING LLP CHINA AS EXTERNAL AUDITOR Beijing– May 15, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May 14, 2013 to replace Ernst & Young LLP Canada. On May] []

By info| 2016-03-24T00:36:21+00:00 May 15th, 2013|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 2013-05-15, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 6-K: SINOVAC APPOINTS ERNST & YOUNG HUA MING LLP

[SINOVAC APPOINTS ERNST & YOUNG HUA MING LLP CHINA AS EXTERNAL AUDITOR Beijing– May 15, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent public accounting firm effective from May 14, 2013 to replace Ernst & Young LLP Canada. On May] []

By info| 2016-03-24T00:38:13+00:00 May 15th, 2013|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 2013-05-15, 2834, 6-K, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: (Original Filing)

[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page No. PART I.FINANCIAL INFORMATION Item 1.ndensednsolidated Financial Statements 3ndensednsolidated Balance Sheets of March 31, 2013 (unaudited) and December 31, 2012 3ndensednsolidated Statements ofmprehensiveome for the Three Months Ended March 31, 2013 and 2012 (unaudited) 4ndensednsolidated Statements ofsh Flows for the Three Months Ended March 31, 2013 and 2012(unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. May 15, 2013 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. May 15, 2013 Bing Mei Chief Financial Officer]

By info| 2016-02-05T02:58:01+00:00 May 15th, 2013|Categories: Chinese Stocks, SEC Original, SKBI|Tags: 0001076939, 10-Q, 2013-05-15, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL] 10-Q: SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page No. PART I.FINANCIAL

[SKYSTAR BIO-PHARMACEUTICALMPANY FORM10-Q INDEX Page No. PART I.FINANCIAL INFORMATION Item 1.ndensednsolidated Financial Statements 3ndensednsolidated Balance Sheets of March 31, 2013 (unaudited) and December 31, 2012 3ndensednsolidated Statements ofmprehensiveome for the Three Months Ended March 31, 2013 and 2012 (unaudited) 4ndensednsolidated Statements ofsh Flows for the Three Months Ended March 31, 2013 and 2012(unaudited)] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THERBANES-OXLEY ACT OF 2002 I, Bing Mei, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q ofystar Bio-Pharmaceuticalmpany; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. May 15, 2013 Weibing Lu Chief Executive Officer] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and result of operations of thempany at thetes and for the periods indicated. May 15, 2013 Bing Mei Chief Financial Officer]

By info| 2016-02-05T02:58:32+00:00 May 15th, 2013|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: 0001076939, 10-Q, 2013-05-15, 2834, PHARMACEUTICAL PREPARATIONS, SKBI|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321033113.htm]

By info| 2016-03-03T16:56:27+00:00 May 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-Q, 2013-05-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x March 31, 2013

[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 73-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321033113.htm]

By info| 2016-03-03T16:57:38+00:00 May 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-Q, 2013-05-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Nevada 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) cphi10qex321033113.htm]

By info| 2016-02-07T21:39:50+00:00 May 14th, 2013|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 10-Q, 2013-05-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x March 31, 2013

[FORM 10-Q (Mark One) x March 31, 2013 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Nevada 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:May 14, 2013 President and Chief Executive Officer (principal financial officer and principal accounting officer) cphi10qex321033113.htm]

By info| 2016-02-07T21:40:28+00:00 May 14th, 2013|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 10-Q, 2013-05-14, 2834, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments